312 CHAPTER 4.1 Table SI1.1. Continued. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) H 8. NSAID with concurrent corticosteroids without PPI prophylaxis 1 0% 0 N/A 1 0% 0 N/A 0 N/A C 7. Ticlopidine in any circumstances. 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A D 3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects (chlorpromazine, clozapine, flupenthixol, fluphenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary retention 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A D 6. Antipsychotics (i.e. other than quetiapine or clozapine) in those with parkinsonism or Lewy Body Disease 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A D 7. Anticholinergics/ antimuscarinics to treat extra-pyramidal side-effects of neuroleptic medications 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A E 5. Colchicine if eGFR < 10 ml/min/1.73m2 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A F 1. Prochlorperazine or metoclopramide with Parkinsonism 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A G 1. Theophylline as monotherapy for COPD 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A H 1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective agents with history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist 0 N/A 0 N/A 0 N/A 0 N/A 0 N/A
RkJQdWJsaXNoZXIy MTk4NDMw